Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 35 - Antineoplastic agents
Patents for A61P 35 - Antineoplastic agents (221,099)
03/2008
03/25/2008US7348314 Double-stranded ribonucleic acid
03/25/2008US7348310 Synthetic methods for aplidine and new antitumoral derivatives, methods of making and using them
03/25/2008US7348148 Polynucleotide analog with polyether, polythioether, polyether sulfone, and/or and polyether sulfoxide linkages; antisense drug therapy
03/25/2008US7348138 Diagnostic methods and kits for identifying individuals exposed to West Nile virus or other viruses including Flavivirus or Pestivirus
03/25/2008US7348032 Using plant extracts as antiproliferative agents
03/25/2008US7348017 such as 2-[Benzyl[(4-methoxyphenyl)sulfonyl]amino]-N-(3-thioxo-3H-1,2,4-dithiazol-5-yl)acetoamide; cosmetics; antiaging agents
03/25/2008US7348000 Therapeutic compositions and methods of treating glycolipid storage related disorders
03/25/2008US7347999 use in bone marrow transplantation, into bone marrow cavity or into extraskeletal sites, such as the kidney capsule, muscles, liver, abdominal wall; treatment of diseases affecting the stromal microenvironment that controls hematopoiesis
03/25/2008CA2426754C Indolocarbazole anticancer agents and methods of using them
03/25/2008CA2419077C A method of treating a systemic disease
03/25/2008CA2333145C Drug delivery system comprising a homeobox peptide and a non-peptide, non-nucleotide drug
03/25/2008CA2277273C Integrin antagonists
03/25/2008CA2264822C Cocoa components, edible products having enhanced polyphenol content, methods of making same and medical uses
03/25/2008CA2243578C High affinity nucleic acid ligands of complement system proteins
03/25/2008CA2203652C A method of down-regulating gene expression
03/25/2008CA2174707C Chromone derivatives as nk1 and substance p antagonists
03/25/2008CA2173319C Radiation sensitization using texaphyrins
03/20/2008WO2008034008A2 Kinase inhibitors useful for the treatment of proliferative diseases
03/20/2008WO2008033999A2 Kinase inhibitors useful for the treatment of proliferative diseases
03/20/2008WO2008033934A1 Substituted heteroaryl carboxylic acid derivatives as ptb-1b inhibitors
03/20/2008WO2008033932A2 Biarylthiazole carboxylic acid derivatives as protein tyrosine phosphatase-ib inhibitors
03/20/2008WO2008033851A2 Use of 2-6- (3-amino-piperidin-l-yl) -3-methyl-2, 4-dioxo-3, 4-dihydr0-2h-pyrimidin-1-ylmet hyl-4-fluoro-benzonitrile
03/20/2008WO2008033834A1 Pyrimidines derivatives and their use as kinase inhibitors
03/20/2008WO2008033567A1 N-methylaminomethyl isoindole compounds and compositions comprising and methods of using the same
03/20/2008WO2008033557A2 Click chemistry-derived cyclic peptidomimetics as integrin markers
03/20/2008WO2008033142A1 Bile preparations for colorectal disorders
03/20/2008WO2008033041A1 Cancer treatment
03/20/2008WO2008033040A1 Combination approaches to cancer treatment
03/20/2008WO2008033039A1 Cancer treatment
03/20/2008WO2008032876A1 Preventive or remedy for er-negative and her2-negative breast cancer and method of screening the same
03/20/2008WO2008032678A1 Adhesive preparation
03/20/2008WO2008032665A1 Novel phenylacetic acid derivative
03/20/2008WO2008032162A1 Pyrido (2, 3-d) pyrimidin0ne compounds and their use as pi3 inhibitors
03/20/2008WO2008032153A2 Calreticulin for its use as a medication for the treatment of cancer in a mammal
03/20/2008WO2008032104A1 One pot synthesis of taxane derivatives and their conversion to paclitaxel and docetaxel
03/20/2008WO2008032091A1 4-benzimidaz0lyl-6-m0rph0lin0-2-piperidin-4-ylpyrimidine derivatives as pi3k and mtor inhibitors for the treatment of proliferative disorders
03/20/2008WO2008032089A1 4-benzimidaz0lyl-2-m0rph0lin0-6-piperidin-4-ylpyrimidine derivatives as pi3k and mtor inhibitors for the treatment of proliferative disorders
03/20/2008WO2008032086A1 2-benzimidazolyl-6-morpholino-4-phenylpyrimidine derivatives as pi3k and mtor inhibitors for the treatment of proliferative disorders
03/20/2008WO2008032077A1 Pyrimidine derivatives
03/20/2008WO2008032072A1 2-benzimidaz0lyl-6-m0rph0lin0-4-piperidin-4-ylpyrimidine derivatives as pi3k and mtor inhibitors for the treatment of proliferative disorders
03/20/2008WO2008032064A1 Pyrimidine derivatives
03/20/2008WO2008032041A1 Pyrimidine derivatives having inhibitory activity against pi3k enzymes
03/20/2008WO2008032036A1 6-benzimidaz0lyl-2-m0rph0lin0-4- (azetidine, pyrrolidine, piperidine or azepine) pyrimidine derivatives as pi3k and mtor inhibitors for the treatment of proliferative disorders
03/20/2008WO2008032033A1 4-benzimidazolyl-2-morpholino-6-piperazinylpyrimidine derivatives as pi3k and mtor inhibitors for the treatment of proliferative disorders
03/20/2008WO2008032028A1 2 -benzimidazolyl- 6 -morpholino-4- (azetidine, pyrrolidine, piperidine or azepine) pyrimidine derivatives as pi3k and mtor inhibitors for the treatment of proliferative disorders
03/20/2008WO2008032027A1 Pyrimidine derivatives
03/20/2008WO2008031842A1 Inhibitors of gpr87 for cancer therapy
03/20/2008WO2008031820A2 Combinations of class-i specific histone deacetylase inhibitors with proteasome inhibitors
03/20/2008WO2008031817A2 Histone deacetylase inhibitors with combined activity on class-i and class-iib histone deacetylases in combination with proteasome inhibitors
03/20/2008WO2008031788A1 Aminoazepine derivatives as highly efficient inhibitors of the inducible nitric oxide synthase
03/20/2008WO2008031594A1 Benzoxazoles and oxazolopyridines being useful as janus kinases inhibitors
03/20/2008WO2008031569A1 Means for increasing intracellular levels of protoporphyrin ix and use thereof
03/20/2008WO2008031531A1 Tumor therapy with a combination of anti-her2 antibodies
03/20/2008WO2008031358A1 1,2-dihydroxy-3-methyl-9,10-anthraquinone in the manufacture of medicaments for treating cancers
03/20/2008WO2008031357A1 (3z)-3-(1h-pyrrol-2-ylmethylene)-1,3-dihydro-2h-indol-2-one in manufacture of medicaments for treating cancers
03/20/2008WO2008031333A1 The prepartion and the use of ethoxy combretastatins and their prodrugs
03/20/2008WO2008031331A1 A recombinant adenovirus target-oriented coexpressing human p53 and p53aip1
03/20/2008WO2008031322A1 Application of acetylcholine esterase inhibitor medication of leonurus extractive as cholinomimetic
03/20/2008WO2008031286A1 Pharmaceutical composition comprising cyclodextrin paclitaxel inclusion and preparation method thereof
03/20/2008WO2008031285A1 Pharmaceutical composition containing docetaxel-cyclodextrin inclusion complex and its preparing process
03/20/2008WO2008031264A1 Furost-5-ene-3, 22, 26-triol glycoside compound for preventing and treating cancer
03/20/2008WO2008031230A1 Methods of determining susceptibility of cells to reovirus infection and methods for treating cellular proliferative disorders with reovirus
03/20/2008WO2008031171A1 Pro-oxidant anti-cancer compounds
03/20/2008WO2008031157A1 Acetylenic compounds
03/20/2008WO2008031126A1 Multi-component tumour vaccine
03/20/2008WO2008016702A3 Combined use of (+)-1,4-dihydro-7-[(3s,4s)-3-methoxy-4-(methylamino)-1-pyrrolidinyl]-4-oxo-1(2-thiazolyl)-1,8-naphthyridine-3-carboxylic
03/20/2008WO2008016700A3 N-oxide compounds for therapeutics uses
03/20/2008WO2008016661A3 Morpholino compounds for treating inflammatory and demyelinating diseases and cancers
03/20/2008WO2008008954A3 Isothiocyanates and glucosinolate compounds and anti-tumor compositios containing same
03/20/2008WO2007147163A3 Compositions comprising carotenoid analogs or derivatives and methods for synthesis
03/20/2008WO2007136510A3 Polymorphic forms of imatinib mesylate and processes for their preparation as well as of amorphous imatinib mesylate and form alpha
03/20/2008WO2007136250A3 A pharmaceutical composition suitable for the treatment of cancer and method of preparing said pharmaceutical composition
03/20/2008WO2007127506A3 Anti-ephrinb2 antibodies and methods using same
03/20/2008WO2007115829A3 Anti ku70 internalizing antibodies
03/20/2008WO2007113648A3 Ctla4 antibody combination therapy
03/20/2008WO2007113198A3 Use of a kinase inhibitor for the treatment of particular resistant tumors
03/20/2008WO2007084391A3 Thiazole compounds as protein kinase b ( pkb) inhibitors
03/20/2008WO2007077531A3 Quinaldine based semisquaraines and squaraine dyes, process for preparation thereof and use thereof
03/20/2008WO2007053502A3 Mutations and polymorphisms of hdac5
03/20/2008WO2007052076A3 Formulations comprising jorumycin-, reni eramycin-, safracin- or saframycin-related compounds for treating proliferative diseases
03/20/2008WO2007022042A3 Combinations comrising a protein kinase inhibitor being a pyrimidylaminobξnzamide compound and a hsp90 inhibitor such as 17-aag
03/20/2008WO2004111075A3 Alternative reading frame polypeptides for treatment
03/20/2008WO2001025398A3 Process for inducing functional tolerance to gene transfer products
03/20/2008US20080071233 Pharmaceutical compositions
03/20/2008US20080071069 For delivering DNA/RNA into cells
03/20/2008US20080071068 Cytoplasmic Localization Dna and Rna
03/20/2008US20080071066 Heparin binding protein for use in controlling angiogenesis and as wound healing agent
03/20/2008US20080071065 Fibroblast Growth Factor-Like Polypeptides
03/20/2008US20080070983 2-O- (Beta-D-Glucopyranosyl) ascorbic acid, process for its production, and foods and cosmetics containing compositions comprising it
03/20/2008US20080070976 Thiophene-2,5-dicarboxylic acid 2-hydroxyamide 5-({1-[4-(4-trifluoromethoxy-benzyloxy)-phenyl]-ethyl}-amide); histone deacetylase inhibitors; anticancer; antiproliferative
03/20/2008US20080070974 4-((1E)-2-(((E)-2-fluoro-4-cyanostyrylsulfonyl)methylsulfonyl)vinyl)-3-fluoro-benzonitrile; mitogen activated protein kinase inhibitor; cell growth factor receptor antagonist; angiogenesis inhibitor, antiproliferative and anticarcinogenic agent; neurodegenerative diseases
03/20/2008US20080070969 [3.2.0] heterocyclic compounds and methods of using the same
03/20/2008US20080070964 Opioid receptor active compounds
03/20/2008US20080070960 Novel 3-Aryl-1,2-Benzisoxazole Derivatives and Use Thereof as Medicinal Products Against Cancer
03/20/2008US20080070957 p-(2-alkoxy-2-acylethyl)biphenyl compounds; 1-[4'-(2-ethoxy-3-morpholin-4-yl-3-oxopropyl)biphenyl-3-yl]-3-heptyl-1-methylurea; human or veterinary medicine: dermatology, cardiovascular diseases, immune diseases,; lipid metabolism diseases; Peroxisome Proliferator-Activated Receptor modulator
03/20/2008US20080070954 inhibitors of histone deacetylase; antiproliferative; anticancer; 8-[3-(4-methylbenzenesulfonyl)-ureido])-octanoic acid hydroxyamide
03/20/2008US20080070950 Amorphous rapamycin 42-ester with 3-hydroxy-2-(hydroxymethyl)-2- methylpropionic acid and its pharmaceutical compositions
03/20/2008US20080070947 Substituted thiophenes: compositions, processes of making, and uses in disease treatment and diagnosis
03/20/2008US20080070940 Side effect reduction of emesis; phosphodiesterase 4 (PDE4) inhibitor; 2-(3'-[3-[(cyclopropylamino)carbonyl)-4-oxo-1,8-naphthyridin-1(4H)-yl]-3-fluoro-1,1'-biphenyl-4-yl)cyclopropanecarboxylic acid, sodium salt; crystalline forms; allergies, autoimmune diseases, cancer, neurodegenerative disorders
03/20/2008US20080070937 Small molecule inhibitors of kynurenine-3-monooxygenase
1 ... 980 981 982 983 984 985 986 987 988 989 990 991 992 993 994 995 996 997 998 999 1000 ... 2211